Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate

Figures & data

Table 1. Comparison of baseline characteristics between the trial and control groups before TURP.

	Trial group (n = 45)	Control group (n = 42)	p Value
Age	70.1 ± 8.8	72.3 ± 5.8	0.17
PV (mL)	105.1 ± 15.6	104.2 ± 17.9	0.90
PSA (ng/mL)	7.3 ± 0.7	7.4 ± 1.0	0.59
PVR (mL)	262.1 ± 20.3	262.7 ± 24.7	0.89
Qm (mL/s)	5.8 ± 3.0	6.2 ± 3.1	0.54
PdetQm (cmH2O)	74.6 ± 30.1	75.1 ± 39.2	0.94
IPSS	24.2 ± 4.5	23.3 ± 5.8	0.42
QoL	4.7 ± 1.0	5.0 ± 0.9	0.14
AUR history	41 (91.1%)	37 (88.0%)	0.73
HU history	14 (31.1%)	14 (33.3%)	0.82
UTI history	12 (26.7%)	11 (26.1%)	0.96

PV: prostate volume, PSA: prostate-specific antigen, PVR: post-void residual volume, Qm: maximum urine flow rate, PdetQm: pressure of detrusor at Qm, IPSS: International Prostate Symptom Score, QoL: quality of life, AUR: acute urinary retention, HU: hematuria, UTI: urinary tract infection.

Table 2. Comparison between trial and control group peri-TURP variables.

	Trial group (n = 45)	Control group (n = 42)	p Value
OM (min)	88.1 ± 23.4	86.0 ± 32.1	0.73
RR (%)	43.1 ± 3.2	42.3 ± 4.7	0.35
CDAO (days)	3.1 ± 1.0	3.2 ± 1.2	0.67
HDAO (days)	4.5 ± 1.0	4.7 ± 1.3	0.42

OM: operation minutes, RR: resection ratio, CDAO: catheterization days after operation, HDAO: hospitalized days after operation.

Table 3. Comparison between the trial and control groups at the six-month follow-up after TURP.

	Trial group (n = 45)	Control group (n = 42)	p Value
PV (mL)	60.2 ± 7.8	62.4 ± 5.4	0.13
PSA (ng/mL)	3.9 ± 0.5	6.0 ± 0.7	<0.001
Qm (mL/s)	18.4 ± 3.2	17.3 ± 4.0	0.16
IPSS	8.1 ± 3.7	8.5 ± 2.9	0.57
QoL	2.8 ± 0.6	2.6 ± 0.8	0.19
PVR (mL)	14.2 ± 5.6	15.7 ± 4.9	0.19
HU	2 (4.4%)	10 (23.8%)	0.01
UTI	4 (8.9%)	7 (16.7%)	0.27
Re-TURP	1 (2.2%)	1 (2.4%)	1.00

PV: prostate volume, PSA: prostate-specific antigen, Qm: maximum urine flow rate, IPSS: the International Prostate Symptom Score, QoL: quality of life, PVR: post-void residual volume, HU: hematuria, UTI: urinary tract infection, Re-TURP: retreatment with TURP.

Table 4. Comparison between finasteride-treated and dutastride-treated patients in the trial group at the six-month follow-up after TURP.

	Finasteride group (n = 29)	Dutastride group (n = 16)	p Value
PV (mL)	61.0 ± 5.8	59.4 ± 5.1	0.34
PSA (ng/mL)	4.0 ± 0.6	3.8 ± 0.4	0.24
Qm (mL/s)	18.9 ± 3.2	17.6 ± 4.2	0.29
IPSS	6.9 ± 3.7	7.3 ± 2.3	0.66
QoL	2.5 ± 0.2	2.7 ± 0.8	0.33
PVR (mL)	13.2 ± 5.1	15.3 ± 4.2	0.14
HU	1 (3.45%)	1 (6.25%)	1.00
UTI	3 (10.34%)	1 (6.25%)	1.00
Re-TURP	1 (3.45%)	0 (0.0%)	1.00

PV: prostate volume, PSA: prostate-specific antigen, Qm: maximum urine flow rate, IPSS: the International Prostate Symptom Score, QoL: quality of life, PVR: post-void residual volume, HU: hematuria, UTI: urinary tract infection, Re-TURP: retreatment with TURP.

Figure 1. Comparison between the trial and control groups at the 3-year follow-up after TURP. PV: prostate volume, PSA: prostate-specific antigen, Qm: maximum urine flow rate, PdetQm: pressure of detrusor at Qm, IPSS: International Prostate Symptom Score, QoL: quality of life, PVR: post-void residual volume, HU: hematuria, UTI: urinary tract infection, Re-TURP: retreatment with TURP.

Figure 2. Comparison between finasteride-treated and dutastride-treated patients in the trial group at the 3-year follow-up after TURP. PV: prostate volume, PSA: prostate-specific antigen, Qm: maximum urine flow rate, PdetQm: pressure of detrusor at Qm, IPSS: the International Prostate Symptom Score, QoL: quality of life, PVR: post-void residual volume, HU: hematuria, UTI: urinary tract infection, Re-TURP: retreatment with TURP.